Scarica l'app Stockscreener
12.80
12.87%
-1.89
Dopo l'orario di chiusura:
12.66
-0.14
-1.09%
Precedente Chiudi:
$14.69
Aprire:
$14.86
Volume 24 ore:
3.87M
Relative Volume:
5.15
Capitalizzazione di mercato:
$691.69M
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-9.9634
EPS:
-1.2847
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
-50.77%
1M Prestazione:
-59.57%
6M Prestazione:
-26.86%
1 anno Prestazione:
+78.77%
Intervallo 1D:
$12.75
$14.86
Intervallo di 1 settimana:
$12.65
$28.57
Portata 52W:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
12.80 | 793.83M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Evercore ISI | Outperform |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Mostra tutto
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio (NASDAQ:UPB) Trading Down 10.3%Time to Sell? - MarketBeat
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB) - Seeking Alpha
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena
Upstream To Upgrade Verekitug To Phase III After Positive Asthma Results - Citeline News & Insights
Upstream Bio (NASDAQ:UPB) Shares Gap DownHere's Why - MarketBeat
VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial - HCPLive
Upstream Bio battered despite positive new verekitug data - The Pharma Letter
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results - TipRanks
UPB: Verekitug cut severe asthma exacerbations by up to 56% with durable efficacy and infrequent dosing - TradingView
Upstream Bio Faces New Strategic Challenges Amid Latest Developments - timothysykes.com
Upstream Bio stock tumbles after mixed Phase 2 asthma trial results - Investing.com Canada
Upstream Bio plunges as asthma drug misses 'home run' bar - TradingView
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio shares plunge 20% premarket after co reports mid-stage asthma drug trial data - marketscreener.com
Upstream Bio reports positive top-line results from the phase 2 Valiant trial of Verekitug for the treatment of severe asthma - marketscreener.com
Upstream Bio Reports Positive Phase 2 Severe Asthma Data - TipRanks
Why Did UPB Stock Pop 20% In Pre-Market Today? - Mena FN
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data - Trefis
UPB: Verekitug showed robust efficacy and safety in severe asthma, advancing to Phase 3 trials - TradingView
Upstream Bio Reports Positive Top-Line Results From The Phase 2 Valiant Trial Of Verekitug For The Treatment Of Severe Asthma - TradingView
Upstream Bio Reports Positive Top-line Results from the - GlobeNewswire
Upstream Bio to report verekitug phase 2 trial results for severe asthma - Investing.com Canada
Upstream Bio To Present Phase 2 VALIANT Trial Results In Severe Asthma, Today - Nasdaq
Upstream Bio to report verekitug phase 2 trial results for severe asthma By Investing.com - Investing.com South Africa
Upstream Bio to reveal Phase 2 trial results for asthma drug - Traders Union
Upstream Bio to Host Webcast to Report Top-Line Results - GlobeNewswire
Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4%Here's What Happened - MarketBeat
Severe Asthma Clinical Trial Analysis: In-Depth Analysis of 50+ - openPR.com
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus PT from Brokerages - Defense World
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6%Should You Sell? - MarketBeat
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BillionToOne, Inc. Class A (BLLN) - The Globe and Mail
Analyst Downgrade: Whats next for Upstream Bio Inc stockWeekly Stock Recap & Reliable Momentum Entry Alerts - baoquankhu1.vn
Stop Loss: What is the next catalyst for Upstream Bio IncChart Signals & Low Risk Entry Point Tips - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Upstream Bio, Inc. (UPB) Stock Analysis: Potential 49.64% Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment - MSN
Will Upstream Bio Inc. stock attract ESG investorsBlue Chip Stock Analysis & Get Ahead with Our Profit-Packed Picks - bollywoodhelpline.com
Aug Setups: What is the next catalyst for Upstream Bio IncEarnings Summary Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug Levels: Is CSGS forming bullish engulfing patterns2025 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BioNano Genomics (BNGO) - The Globe and Mail
Sectors Review: Is Upstream Bio Inc a cyclical or defensive stockTake Profit & Community Verified Trade Alerts - baoquankhu1.vn
Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes - simplywall.st
Can Upstream Bio Inc outperform in the next rallyWeekly Trading Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Upstream Bio stock hits all-time high at 33.05 USD By Investing.com - Investing.com Nigeria
Aug Volume: Is Upstream Bio Inc a defensive stockMarket Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week HighHere's What Happened - MarketBeat
Upstream Bio stock hits all-time high at 33.05 USD - Investing.com
US Market Recap: Can Upstream Bio Inc ride the EV wave2025 Price Action Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):